{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:05:45Z","timestamp":1791083145526,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Distressing nightmares are a core symptom of posttraumatic stress disorder (PTSD) and contribute to psychiatric comorbidity, impaired physical health and decreased social functioning. No specific pharmacological treatment for PTSD-related nightmares is yet approved. Preliminary clinical data indicate that cannabinoid agonists can improve nightmares and overall PTSD symptoms in patients with PTSD. The primary objective of the study is to examine the efficacy of oral dronabinol (BX-1) versus placebo in reducing nightmares in patients with PTSD. The secondary objectives of the study are to examine the efficacy of oral BX-1 in reducing other PTSD symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is designed as a multi-centric, double-blind, randomized (1:1), placebo-controlled, parallel group interventional trial. Eligible patients will be randomized to BX-1 or placebo, receiving a once-daily oral dose before bedtime for 10\u00a0weeks. Primary efficacy endpoint is the Clinician-Administered PTSD Scale (CAPS-IV) B2 score for the last week, measuring frequency and intensity of nightmares. Secondary efficacy endpoints are other disorder-specific symptoms in patients with PTSD. Further, tolerability and safety of dronabinol will be assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This randomized controlled trial will provide evidence whether treating patients with PTSD and nightmares with dronabinol is safe and efficacious.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT04448808, EudraCT 2019\u2013002211-25.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-023-04818-5","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:02:17Z","timestamp":1683266537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial)"],"prefix":"10.1186","volume":"23","author":[{"given":"Stefan","family":"Roepke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Schoofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathlen","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"W\u00fclfing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"R\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Z\u00e4hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"2","key":"4818_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.smrv.2012.06.001","volume":"17","author":"AW Augedal","year":"2013","unstructured":"Augedal AW, Hansen KS, Kronhaug CR, Harvey AG, Pallesen S. Randomized controlled trials of psychological and pharmacological treatments for nightmares: a meta-analysis. Sleep Med Rev. 2013;17(2):143\u201352. https:\/\/doi.org\/10.1016\/j.smrv.2012.06.001.","journal-title":"Sleep Med Rev"},{"issue":"15","key":"4818_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2146\/ajhp140523","volume":"72","author":"K Betthauser","year":"2015","unstructured":"Betthauser K, Pilz J, Vollmer LE. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm. 2015;72(15):1279\u201384. https:\/\/doi.org\/10.2146\/ajhp140523.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"4818_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jts.2490080106","volume":"8","author":"DD Blake","year":"1995","unstructured":"Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75\u201390.\u00a0Retrieved from\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7712061.","journal-title":"J Trauma Stress"},{"issue":"3","key":"4818_CR4","doi-asserted-by":"publisher","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","volume":"16","author":"MO Bonn-Miller","year":"2021","unstructured":"Bonn-Miller MO, Sisley S, Riggs P, Yazar-Klosinski B, Wang JB, Loflin MJE, Doblin R. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLoS One. 2021;16(3):e0246990. https:\/\/doi.org\/10.1371\/journal.pone.0246990.","journal-title":"PLoS One"},{"issue":"4","key":"4818_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/jts.20243","volume":"20","author":"MO Bonn-Miller","year":"2007","unstructured":"Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20(4):577\u201386. https:\/\/doi.org\/10.1002\/jts.20243.","journal-title":"J Trauma Stress"},{"issue":"3","key":"4818_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1176\/ajp.153.3.369","volume":"153","author":"JD Bremner","year":"1996","unstructured":"Bremner JD, Southwick SM, Darnell A, Charney DS. Chronic PTSD in Vietnam combat veterans: Course of illness and substance abuse. Am J Psychiatry. 1996;153(3):369\u201375.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"4818_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11920-015-0587-8","volume":"17","author":"JA Brownlow","year":"2015","unstructured":"Brownlow JA, Harb GC, Ross RJ. Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature. Curr Psychiatry Rep. 2015;17(6):41. https:\/\/doi.org\/10.1007\/s11920-015-0587-8.","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"4818_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/Jcp.0000000000000180","volume":"34","author":"C Cameron","year":"2014","unstructured":"Cameron C, Watson D, Robinson J. Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder-Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications A Retrospective Evaluation. J Clin Psychopharmacol. 2014;34(5):559\u201364. https:\/\/doi.org\/10.1097\/Jcp.0000000000000180.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4818_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"key":"4818_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1749-6632.2010.05793.x","volume":"1208","author":"J Cukor","year":"2010","unstructured":"Cukor J, Olden M, Lee F, Difede J. Evidence-based treatments for PTSD, new directions, and special challenges. Ann N Y Acad Sci. 2010;1208:82\u20139. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05793.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"4818_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","volume":"15","author":"GA Fraser","year":"2009","unstructured":"Fraser GA. The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84\u20138. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00071.x.","journal-title":"CNS Neurosci Ther"},{"key":"4818_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","volume":"51","author":"R Jetly","year":"2015","unstructured":"Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585\u20138. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.11.002.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"4818_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/tra0000384","volume":"11","author":"SE Larsen","year":"2019","unstructured":"Larsen SE, Fleming CJE, Resick PA. Residual symptoms following empirically supported treatment for PTSD. Psychol Trauma. 2019;11(2):207\u201315. https:\/\/doi.org\/10.1037\/tra0000384.","journal-title":"Psychol Trauma"},{"issue":"5","key":"4818_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1037\/tra0000254","volume":"9","author":"E Monson","year":"2017","unstructured":"Monson E, Caron J, McCloskey K, Brunet A. Longitudinal analysis of quality of life across the trauma spectrum. Psychol Trauma. 2017;9(5):605\u201312. https:\/\/doi.org\/10.1037\/tra0000254.","journal-title":"Psychol Trauma"},{"issue":"8","key":"4818_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/PSY.0b013e3182303775","volume":"73","author":"RH Pietrzak","year":"2011","unstructured":"Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Medical comorbidity of full and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2011;73(8):697\u2013707. https:\/\/doi.org\/10.1097\/PSY.0b013e3182303775.","journal-title":"Psychosom Med"},{"issue":"3","key":"4818_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","volume":"25","author":"RH Pietrzak","year":"2011","unstructured":"Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456\u201365. https:\/\/doi.org\/10.1016\/j.janxdis.2010.11.010.","journal-title":"J Anxiety Disord"},{"issue":"8","key":"4818_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","volume":"61","author":"MA Raskind","year":"2007","unstructured":"Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, McFall ME. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatr. 2007;61(8):928\u201334. https:\/\/doi.org\/10.1016\/j.biopsych.2006.06.032.","journal-title":"Biol Psychiatr"},{"issue":"8","key":"4818_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","volume":"34","author":"P Roitman","year":"2014","unstructured":"Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34(8):587\u201391. https:\/\/doi.org\/10.1007\/s40261-014-0212-3.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"4818_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archgenpsychiatry.2011.15","volume":"68","author":"J Sareen","year":"2011","unstructured":"Sareen J, Afifi TO, McMillan KA, Asmundson GJ. Relationship between household income and mental disorders: findings from a population-based longitudinal study. Arch Gen Psychiatry. 2011;68(4):419\u201327. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.15.","journal-title":"Arch Gen Psychiatry"},{"issue":"25","key":"4818_CR20","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1056\/NEJMra1612499","volume":"376","author":"A Shalev","year":"2017","unstructured":"Shalev A, Liberzon I, Marmar C. Post-Traumatic Stress Disorder. N Engl J Med. 2017;376(25):2459\u201369. https:\/\/doi.org\/10.1056\/NEJMra1612499.","journal-title":"N Engl J Med"},{"key":"4818_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1201\/b11826","volume-title":"Flexible imputation of missing data. Chapter 2. Multiple imputation","author":"S Van Buuren","year":"2012","unstructured":"Van Buuren S. Flexible imputation of missing data. Chapter 2. Multiple imputation. Boca Raton: Chapman and Hall\/CRC Press; 2012. p. 25\u201352."},{"key":"4818_CR22","unstructured":"World Health Organization. Mortality and Burden of Disease Estimates for WHO Member States: Persons, all ages; 2004. (xls). Retrieved 2009-11-12."},{"issue":"8","key":"4818_CR23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4088\/JCP.15r10036","volume":"77","author":"ST Wilkinson","year":"2016","unstructured":"Wilkinson ST, Radhakrishnan R, D\u2019Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. J Clin Psychiatry. 2016;77(8):1050\u201364. https:\/\/doi.org\/10.4088\/JCP.15r10036.","journal-title":"J Clin Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04818-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:04:51Z","timestamp":1683266691000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04818-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4818"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04818-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by a German ethics committee\u2014Ethik-Kommission des Landes Berlin (Reference: 19\/0384 \u2013 IV E 11) on January 22, 2020 (see\n                      \n                      for approval). The study was performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"S.R. reports personal fees from Janssen, Otsuka, Bionorica SE (prior to signature of study contract), Boehringer Ingelheim, and Stillachhaus outside the submitted work and reports grants from the German Research Foundation (DFG), German Ministry of Education and Research (BMBF), and Innovationsfond. N.S., K.P., F.W., R.R., J.Z., T.L., and S.K. report no COI. C.S. reports personal fees from Boehringer Ingelheim outside the submitted work. C.O. reports honoraria for lectures and\/or scientific advice from Janssen, Limes Klinikgruppe, Lundbeck, Neuraxpharm, and Peak Profiling, and research funding from the Deutsche Forschungsgemeinschaft (OT 209\/7\u20133; 14\u20131, 19\u20131, EXC 2049), the European Commission (IMI2 859366), the German Federal Ministry of Education and Research (KS2017-067), and the Berlin Institute of Health (B3010350).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}